Drug Price Trends for NDC 72603-0324

Average Pharmacy Cost for 72603-0324

Drug Name	NDC	Price/Unit ($)	Unit	Date
LOTEPREDNOL ETABONATE 0.5% DRP	72603-0324-02	8.97947	ML	2025-04-23
LOTEPREDNOL ETABONATE 0.5% DRP	72603-0324-03	25.60538	ML	2025-04-23
LOTEPREDNOL ETABONATE 0.5% DRP	72603-0324-01	19.40425	ML	2025-04-23
LOTEPREDNOL ETABONATE 0.5% DRP	72603-0324-01	18.52039	ML	2025-03-19
LOTEPREDNOL ETABONATE 0.5% DRP	72603-0324-03	25.14770	ML	2025-03-19
LOTEPREDNOL ETABONATE 0.5% DRP	72603-0324-02	11.57471	ML	2025-03-19

Best Wholesale Price for NDC 72603-0324

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

72603-0324 Market Analysis and Financial Projection

The drug with NDC 72603-0324 (Loteprednol Etabonate) is a corticosteroid used to treat inflammatory eye conditions. While specific price data for this NDC is unavailable in the provided sources, broader market trends for NorthStar RxLLC’s generic drugs offer insights for analysis and projections.

---

Current Market Position

• Generic Competition: NorthStar RxLLC’s portfolio includes mature generics like Cyclophosphamide ([72603-411][1]) and Icosapent Ethyl ([72603-129][4]), which face price erosion of 5–7% annually due to competition[2].
• Application Category: Marketed under ANDA (Abbreviated New Drug Application), indicating it is a generic equivalent[1][4].

---

Price Trends and Projections

Timeframe	Projection	Basis
Short-Term (1–2 years)	Prices likely to decline by 1–3% annually due to generic saturation[7].	Aligns with trends observed in Mesalamine (NDC 72603-0304)[7].
Medium-Term (3–5 years)	Accelerating price erosion (up to 7% annually) if new competitors enter.	Matches Cyclophosphamide’s trajectory under similar market conditions[2].
Long-Term (>5 years)	Stabilization at lower price tiers, contingent on formulary placements.	Reflects lifecycle patterns of aging generics with limited differentiation.

---

Key Considerations

1. Regulatory Environment: ANDA approvals for Loteprednol Etabonate could invite additional competitors, intensifying pricing pressures.
2. Therapeutic Class: Corticosteroids are a crowded market, limiting pricing power without novel formulations[6].
3. Manufacturer Strategy: NorthStar RxLLC may prioritize volume over price retention, as seen with Cyclophosphamide[1].

---

Strategic Recommendations

• Cost-Plus Pricing: Align with benchmarks like Icosapent Ethyl ($6.64–$7.44 per unit)[2] to maintain formulary inclusion.
• Differentiation: Explore sustained-release formulations or combo therapies to mitigate commoditization.

---

“Price erosion is unavoidable for mature generics, but strategic portfolio management can offset margin compression.” – Industry Analysis[2].

This analysis synthesizes comparable NDC trends, though direct data for 72603-0324 remains limited.

[1][2][4][6][7]

References

1. https://fda.report/NDC/72603-411
2. https://www.drugpatentwatch.com/p/drug-price/ndc/72603-0317
3. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6db749b9-c817-41cd-909f-dd60a90c9f73
4. https://fda.report/NDC/72603-129
5. https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/72603-0103/
6. https://www.findacode.com/ndc/labelers/NorthStar_RxLLC--72603
7. https://www.drugpatentwatch.com/p/drug-price/ndc/72603-0304